Knowledge gained from structural and functional studies using activators or inhibitors of the potassium current mediated by KV4/KChIPs will contribute to understanding the mechanisms involved in the KV4-mediated-channelopathies and to establish the bases of drug discovery to treat them. This evidence concerns the gene KCNC1 and channelopathy.